viewHumanigen, Inc.

Humanigen strengthens leadership team with three new executive appointments

It appointed Dale Chappell as chief scientific officer, David Tousley as treasurer, chief accounting and administrative officer and Omar Ahmed as senior vice president of medical and scientific affairs

Humanigen, Inc. -
The appointments provide Humanigen with both continuity and bench strength as the firm advances work on lenzilumab

Humanigen Inc (OTCMKTS:HGEN) bolstered its leadership team with the addition of three new executives, it reported Tuesday.

The California-based biopharmaceutical company has appointed Dale Chappell as chief scientific officer, David Tousley as chief accounting and administrative officer, corporate secretary and treasurer and Omar Ahmed as senior vice president, clinical, medical and scientific affairs.

The appointments provide Humanigen with both continuity and bench strength as the firm advances work on lenzilumab, which is being investigated as a potential treatment for cytokine storms caused by the coronavirus infection. 

READ: Humanigen reveals first patient has been infused in ZUMA-19 study

Chapell is a former Howard Hughes Medical Institute fellow at the National Cancer Institute, studying tumor immunology and publishing in the field of T-cell therapy, immunology pathways, and GM-CSF.

Tousley has held C-suite roles at companies including Pasteur Merieux Connaught (now Sanofi Pasteur), AVAX Technologies Inc and DARA Biosciences.

Ahmed has over 20 years of executive leadership experience, including advancing Janssen’s $10 billion global immunology portfolio from early development to late-stage development as well as leadership positions at Novartis and Roche Pharmaceuticals.

“We are pleased that both Dr Chappell and Mr Tousley, who have previously operated in interim capacities with the company, have joined us as full-time members of the Humanigen team,” Humaigen CEO Cameron Durrant said in a statement.

“Their appointments, along with Dr Ahmed’s promotion, provide us with continuity and ongoing scientific and operational bench strength as we move the company forward. Filling these key leadership roles with proven executives who are highly regarded within the biotechnology sector, and who have been deeply involved with the strategic direction of our company, is a next step in our plan to rapidly grow into an organization committed to bringing important therapies to patients around the globe.”

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Humanigen, Inc.

Price: - -

Market: OTCQB
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...


Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

2 min read